Thoma Bravo Is Taking Accelerant Private for $20.25 a Share — Still Below Its Own IPO Price

A 49% cash premium sent $ARX up almost 45% before the bell — and yet the buyout price is still less than what public investors paid at the IPO thirteen months ago. Both of those things are true at once, and that tension is the whole story.

There are two ways to read a takeover premium. The first is the way the tape read it at 6:30 this morning: Thoma Bravo agreed to buy Accelerant Holdings for $20.25 a share in cash, a 49% premium to Tuesday’s close, and $ARX promptly gapped from $13.61 to roughly $19.69 in pre-market trade — a move of about 44.7%. The second way is less flattering. Accelerant went public on the New York Stock Exchange in July 2025 at $21.00 a share, so the “premium” being celebrated this morning is a price below what the IPO book paid just over a year ago. The deal terms are in the company’s definitive-agreement release, the IPO pricing in Seeking Alpha’s coverage and the company’s own completion announcement, and the price and volume history at StockAnalysis.

This profile walks through what Accelerant agreed to, the second-quarter numbers it released ninety minutes later, how a specialty-insurance “risk exchange” earns its money, why a software buyout firm wanted it, and what is left in the trade now that the premium is already on the screen.

Company snapshot

• Company: Accelerant Holdings  ·  Ticker: ARX (NYSE)
• Sector: Financials · Specialty insurance / risk exchange
• Registered office: George Town, Cayman Islands · Founded 2018
• CEO: Jeff Radke (co-founder and chief executive)
• Three segments: Exchange Services · MGA Operations · Underwriting
• Listed: IPO priced July 2025 at $21.00 per Class A share; backed by Altamont Capital Partners
• Approx. market cap: ~$2.97B on ~218.2M shares  ·  52-week range: $9.18 – $30.48

Snapshot figures are drawn from the company’s SEC filings, its IPO announcements and StockAnalysis; the deal terms and quarterly results are sourced below.

What actually happened

At 6:30 a.m. Eastern on August 13, Accelerant announced it had entered a definitive agreement to be acquired by Thoma Bravo in an all-cash transaction valuing the business at an enterprise value of more than $4 billion. Holders of both Class A and Class B shares receive the same $20.25 per share in cash. The transaction is expected to close in the first half of 2027, subject to shareholder approval and to the regulatory clearances that any change of control in insurance requires.

Three structural details matter more than the headline number. There is no financing condition — Thoma Bravo has provided an equity commitment to fund the purchase, removing the most common way a private-equity deal falls apart. Entities affiliated with Altamont Capital Partners, holding approximately 82% of outstanding voting rights, have already agreed to vote in favour, so the shareholder vote is effectively decided. And the agreement carries a ticking fee accruing at 6% per annum under certain circumstances if closing is delayed by pending insurance regulatory approvals — an acknowledgement, written into the contract, that the parties expect to wait.

Ninety minutes later, at 7:24 a.m. Eastern, Accelerant published second-quarter 2026 results. It cancelled the 8:00 a.m. conference call it had scheduled and declined to give third-quarter or full-year guidance, citing the pending transaction. That is standard for a company that has just agreed to be bought, but it is worth stating plainly: from this morning forward, ARX is a merger-arbitrage instrument, not a company the market will price on its next quarter.

The numbers behind the morning

Sources: Accelerant’s August 13, 2026 definitive-agreement release and Q2 2026 results release; StockAnalysis for price, share count and volume. Adjusted figures are non-GAAP as reported by the company.

Strip the deal away and this was a good quarter. Revenue of $356.9 million against $219.1 million is growth of roughly 63%. Exchange written premium — the volume flowing across the platform, and the number that best describes whether the marketplace is working — rose 23% to $1.32 billion. Adjusted EBITDA of $93.1 million on a 31% margin is the profile of a business with real operating leverage rather than one buying growth. Third-party direct written premium accounted for 47% of exchange volume, a measure of how much risk on the platform is carried by outside capital rather than Accelerant’s own balance sheet.

Twelve months of tape

The chart is the part of the story the premium headline hides. ARX has traded between $9.18 and $30.48 over the past year and was down roughly 52% over that window heading into this morning. The stock was not taken out from a position of strength; it was taken out after losing half its value from the highs. A 49% premium applied to a badly damaged price is still a damaged price — which is precisely why $20.25 lands under the $21.00 IPO level.

Inside the business: three ways to earn a dollar

Accelerant is not a conventional insurer, and the distinction matters for understanding why a technology buyout firm is the acquirer. It operates the Accelerant Risk Exchange, a data-driven marketplace connecting specialty insurance underwriters — managing general agents, or MGAs — with the risk capital that ultimately backs the policies they write. Its filings break the economics into three segments.

Exchange Services is the platform itself: the technology, the data ingestion and the agency operations that serve members and risk-capital partners. When capital partners write premium directly through the exchange, they pay Accelerant a fixed-percentage, volume-based fee for sourcing, managing and monitoring that business. This is the asset-light, recurring, software-like layer — the part of Accelerant that most resembles what Thoma Bravo usually buys.

MGA Operations captures the fees member agencies earn for originating and underwriting portfolios of policies, net of the cost of serving them. Accelerant also takes selective equity participations in members, letting it keep a share of the value the exchange helps create rather than only clipping a fee on the way past.

Underwriting is the largest revenue contributor and the most traditional: policies underwritten and reinsurance assumed by Accelerant’s own consolidated insurance and reinsurance companies. It carries actual insurance risk, and it is what makes Accelerant something other than a pure software story.

That mix explains both the appeal and the complexity. The exchange layer scales like a marketplace; the underwriting layer is a regulated balance sheet that has to be approved, jurisdiction by jurisdiction, before anyone can buy it.

Why Thoma Bravo, and why now

Thoma Bravo describes itself as the world’s largest software-focused investment firm, with more than $172 billion in assets under management as of March 31, 2026, and roughly 590 software and technology companies acquired or invested in over its history. Accelerant fits that thesis if you accept the framing that it is a technology platform which happens to sit inside insurance rather than an insurer that happens to own software. The recurring, volume-based fee stream in Exchange Services is exactly the kind of revenue such a buyer underwrites against.

Timing is the more revealing part. A firm with 23% premium growth and 31% adjusted EBITDA margins would not normally sell thirteen months after listing. It sells when the public market has stopped paying for what it is building — and a stock down roughly 52% over a year on the eve of a good print is a fairly precise definition of that. Altamont Capital Partners, the pre-IPO backer that still controls about 82% of the voting power, and the founders intend to retain equity alongside Thoma Bravo. The people closest to the business are, in effect, choosing to keep owning it privately rather than publicly.

The case for caution

The single most important fact for anyone looking at ARX this morning: the upside is now capped by contract. At roughly $19.69 pre-market against a $20.25 deal price, there is about 2.8% left — and that is not a stock’s upside, it is a spread. Nothing Accelerant does operationally between now and closing changes what a shareholder receives. Good quarters will not raise it; soft quarters will not lower it.

Against that 2.8% sit three real risks. The first is time: closing is expected in the first half of 2027, so capital is committed for the better part of a year to earn a low-single-digit return. Annualise that spread and it is unremarkable next to a Treasury bill. The 6% ticking fee compensates for delay in certain circumstances, but it is a contractual backstop, not a yield to assume.

The second is regulatory. Change-of-control approvals for insurance and reinsurance entities are granted by individual regulators across multiple jurisdictions, and the parties clearly anticipate friction — otherwise the ticking fee would not be in the document. Deals of this shape rarely collapse at the regulatory stage, but they often run late.

The third is the absence of an alternative. With roughly 82% of voting rights already committed, a competing bidder has essentially no path, so anyone buying today hoping a rival pushes the price higher is buying against arithmetic that is already settled. And if the deal broke, the reference point is not $20.25 — it is the $13.61 the stock closed at on Tuesday, or lower.

What to watch next

The near-term tell is where the spread settles once the market opens. A stock trading tight to $20.25 is the market pricing high confidence and a short wait; a persistent discount is the market pricing regulatory delay. After that, the meaningful dates are the proxy filing and shareholder vote, then the sequence of insurance approvals that sets the actual closing date. With guidance withdrawn and the call cancelled, quarterly results from here are informational rather than price-setting.

The bottom line

Accelerant delivered a genuinely strong quarter and simultaneously agreed to stop being a public company, and the second fact has entirely consumed the first. The 49% premium is real, the cash is real, and the vote is effectively locked. But the premium was almost fully paid before most investors saw a quote this morning, the buyout price sits below the $21.00 IPO price, and what remains is a roughly 2.8% spread that requires waiting into 2027 and clearing insurance regulators in several jurisdictions to collect. For anyone who owned ARX yesterday, this is a welcome end to a bad year. For anyone considering it this morning, it is no longer a story about specialty insurance at all — it is a bet on a closing date.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. TopStockPicks.co is not a registered investment advisor and is not a broker-dealer. TopStockPicks.co has NOT BEEN COMPENSATED for coverage of ARX. TopStockPicks.co and its affiliates or officers may buy and sell shares of ARX in the open market at any time without notice. TopStockPicks.co does not set price targets on securities. Always do your own due diligence and consult your financial advisor. Never invest into a stock discussed by TopStockPicks.co unless you can afford to lose your entire investment.